Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
AbstractGolimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
- Abstract views: 1739
- PDF: 1781
Copyright (c) 2015 M. Rossini, O Viapiana, G. Orsolini, E. Fracassi, L. Idolazzi, D. Gatti, S. Adami, M. Govoni
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.